454 related articles for article (PubMed ID: 29071331)
1. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J
JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331
[TBL] [Abstract][Full Text] [Related]
2. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
Schwartz GG; Abt M; Bao W; DeMicco D; Kallend D; Miller M; Mundl H; Olsson AG
J Am Coll Cardiol; 2015 Jun; 65(21):2267-75. PubMed ID: 26022813
[TBL] [Abstract][Full Text] [Related]
3. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
[TBL] [Abstract][Full Text] [Related]
4. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.
Pitts R; Gunzburger E; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; Nicholls SJ; Shah PK; Tardif JC; Olsson AG; McMurray JJ; Kittelson J; Schwartz GG
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28073769
[TBL] [Abstract][Full Text] [Related]
6. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
Salahuddin T; Kittelson J; Tardif JC; Shah PK; Olsson AG; Nicholls SJ; Leitersdorf E; Leiter LA; Kallend D; Black DM; Barter PJ; Ballantyne CM; Schwartz GG
Am Heart J; 2020 Mar; 221():60-66. PubMed ID: 31927126
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
Schwartz GG; Olsson AG; Ballantyne CM; Barter PJ; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Shah PK; Tardif JC; Chaitman BR; Duttlinger-Maddux R; Mathieson J;
Am Heart J; 2009 Dec; 158(6):896-901.e3. PubMed ID: 19958854
[TBL] [Abstract][Full Text] [Related]
8. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
[TBL] [Abstract][Full Text] [Related]
9. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
[TBL] [Abstract][Full Text] [Related]
10. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
[TBL] [Abstract][Full Text] [Related]
11. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes.
Gencer B; Rigamonti F; Nanchen D; Vuilleumier N; Kern I; Aghlmandi S; Klingenberg R; Räber L; Auer R; Carballo D; Carballo S; Heg D; Windecker S; Lüscher TF; Matter CM; Rodondi N; Mach F
Eur J Clin Invest; 2019 Jul; 49(7):e13117. PubMed ID: 30937890
[TBL] [Abstract][Full Text] [Related]
14. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
[TBL] [Abstract][Full Text] [Related]
15. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke.
Lange KS; Nave AH; Liman TG; Grittner U; Endres M; Ebinger M
Stroke; 2017 Jan; 48(1):36-42. PubMed ID: 27856951
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.
Tardif JC; Pfeffer MA; Kouz S; Koenig W; Maggioni AP; McMurray JJV; Mooser V; Waters DD; Grégoire JC; L'Allier PL; Wouter Jukema J; White HD; Heinonen T; Black DM; Laghrissi-Thode F; Levesque S; Guertin MC; Dubé MP;
Eur Heart J; 2022 Oct; 43(39):3947-3956. PubMed ID: 35856777
[TBL] [Abstract][Full Text] [Related]
20. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.
Lopes RD; de Barros E Silva PGM; de Andrade Jesuíno I; Santucci EV; Barbosa LM; Damiani LP; Nakagawa Santos RH; Laranjeira LN; Dall Orto FTC; Beraldo de Andrade P; de Castro Bienert IR; Alexander JH; Granger CB; Berwanger O
JAMA Cardiol; 2018 Nov; 3(11):1113-1118. PubMed ID: 30264159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
